Regeneron Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Vanguard Capital Management has reported a beneficial ownership of 7.37% in Regeneron Pharmaceuticals Inc., holding over 7.6 million shares as of March 31, 2026.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Regeneron Pharmaceuticals Inc. following an internal realignment where subsidiaries will now report separately.
NASDAQ
SCHEDULE: FMR LLC Amends Regeneron Stake to 3.2%
FMR LLC and Abigail P. Johnson have filed an Amendment No. 7 to their Schedule 13G, reporting a 3.2% beneficial ownership stake in Regeneron Pharmaceuticals Inc. as of June 30, 2025.
NASDAQ
JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting a 4.4% beneficial ownership stake in Regeneron Pharmaceuticals, Inc. as of May 30, 2025.
NASDAQ
JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting a 5.1% beneficial ownership stake in Regeneron Pharmaceuticals, Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 7.6% Passive Stake in Regeneron Pharmaceuticals
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 7.6% beneficial ownership stake in Regeneron Pharmaceuticals Inc. as of December 31, 2024.